Kyle O Rove

Summary

Affiliation: University of Colorado Denver
Country: USA

Publications

  1. ncbi Role of testosterone in managing advanced prostate cancer
    Kyle O Rove
    University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
    Urology 80:754-62. 2012
  2. ncbi Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts
    Kyle O Rove
    Division of Urology, University of Colorado, Anschutz Medical Campus, Mail Stop F710, P O Box 6510, Aurora, CO 80045, USA
    World J Urol 30:137-42. 2012
  3. ncbi Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival
    Kyle O Rove
    Section of Urologic Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 25:1362-70, 1375-81, 1387. 2011
  4. ncbi Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
    BJU Int 108:1743-9. 2011
  5. ncbi Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado Electronic address
    J Urol 188:1726-31. 2012
  6. ncbi The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer
    Al B Barqawi
    Division of Urology, University of Colorado Denver, Aurora, Colorado, USA
    J Urol 186:80-5. 2011
  7. ncbi Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro
    Abdalla Ali Deb
    Program in Urosciences, Division of Urology, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    J Urol 186:2426-33. 2011
  8. ncbi The computerized rounding report: implementation of a model system to support transitions of care
    Max V Wohlauer
    Department of Surgery, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, USA
    J Surg Res 172:11-7. 2012
  9. ncbi A renaissance in the medical treatment of advanced prostate cancer
    Kyle O Rove
    Division of Urology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA
    Oncology (Williston Park) 24:1308-13, 1318. 2010
  10. ncbi High-intensity focused ultrasound: ready for primetime
    Kyle O Rove
    Division of Urology, University of Colorado Anschutz Medical Campus, 12631 East 17th Avenue, Mailstop C302, Aurora, CO 80045, USA
    Urol Clin North Am 37:27-35, Table of Contents. 2010

Detail Information

Publications11

  1. ncbi Role of testosterone in managing advanced prostate cancer
    Kyle O Rove
    University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
    Urology 80:754-62. 2012
    ..Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process...
  2. ncbi Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts
    Kyle O Rove
    Division of Urology, University of Colorado, Anschutz Medical Campus, Mail Stop F710, P O Box 6510, Aurora, CO 80045, USA
    World J Urol 30:137-42. 2012
    ..This report aims to clarify the issues specific to the PSA test, prostate cancer, sources of bias, and the future of screening...
  3. ncbi Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival
    Kyle O Rove
    Section of Urologic Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 25:1362-70, 1375-81, 1387. 2011
    ....
  4. ncbi Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, 80045, USA
    BJU Int 108:1743-9. 2011
    ..This study examines a larger number of men in a diverse US population to determine the prognostic value of a man's baseline or first PSA...
  5. ncbi Diagnostic Performance of PCA3 to Detect Prostate Cancer in Men with Increased Prostate Specific Antigen: A Prospective Study of 1,962 Cases
    E David Crawford
    University of Colorado, Anschutz Medical Campus, Aurora, Colorado Electronic address
    J Urol 188:1726-31. 2012
    ..We investigated the value of the PCA3 (prostate cancer gene 3) urine test in predicting the likelihood of diagnosis of cancer before biopsy...
  6. ncbi The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer
    Al B Barqawi
    Division of Urology, University of Colorado Denver, Aurora, Colorado, USA
    J Urol 186:80-5. 2011
    ..We determined the impact of a grid based, transperineal 3-dimensional mapping biopsy on decision making for primary management of early stage prostate cancer...
  7. ncbi Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro
    Abdalla Ali Deb
    Program in Urosciences, Division of Urology, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    J Urol 186:2426-33. 2011
    ..We examined the effect of the combination of valproic acid and mitomycin C on human bladder cancer cells in vitro and compared this to the effect of valproic acid or mitomycin C alone on the cells...
  8. ncbi The computerized rounding report: implementation of a model system to support transitions of care
    Max V Wohlauer
    Department of Surgery, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, USA
    J Surg Res 172:11-7. 2012
    ..Patient safety is an issue with this new paradigm. We hypothesized that computerized sign-out would improve resident efficiency...
  9. ncbi A renaissance in the medical treatment of advanced prostate cancer
    Kyle O Rove
    Division of Urology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA
    Oncology (Williston Park) 24:1308-13, 1318. 2010
    ..In recent years, however, new therapies have begun to emerge to treat this devastating form of prostate cancer. This review examines the mechanisms behind these therapeutics and the key trials seeking to validate their clinical use...
  10. ncbi High-intensity focused ultrasound: ready for primetime
    Kyle O Rove
    Division of Urology, University of Colorado Anschutz Medical Campus, 12631 East 17th Avenue, Mailstop C302, Aurora, CO 80045, USA
    Urol Clin North Am 37:27-35, Table of Contents. 2010
    ..The HIFU technique, its mechanism of action, patient selection, current efficacy studies, complications, follow-up after HIFU treatment, and future developments are discussed...
  11. ncbi Metastatic cancer in solid tumors and clinical outcome: skeletal-related events
    Kyle O Rove
    University of Colorado Cancer Center, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
    Oncology (Williston Park) 23:21-7. 2009
    ....